In a study of 11 medical-mystery patients, an international team of researchers led by scientists at the National Institutes of Health and the Uniformed Services University discovered a new and unique form of amyotrophic lateral sclerosis (ALS).
Brain injury research to focus on moderate concussion ucr.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ucr.edu Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK, May 27, 2021 /PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
Under orphan designation in the European Union (EU), Seelos stands to benefit from several incentives such as protocol assistance, reduced regulatory fees and market exclusivity. European guidelines for Orphan Drug Designation are for diseases affecting not more than five in 10,000 people in the EU.
The National Institutes of Health (NIH) recently awarded Amy Bastian, Ph.D., PT, chief science officer and director of the Motion Analysis Lab at Kennedy Krieger Institute, with an eight-year, $4.7 million National Institute of Neurological Disorders and Stroke (NINDS) Research Program Award (N35) to support a study examining movement learning mechanisms and how this process is affected by brain damage.